Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?

Am Heart J. 2005 Oct;150(4):650-1. doi: 10.1016/j.ahj.2005.08.001.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • C-Reactive Protein / analysis*
  • Coronary Disease / blood*
  • Coronary Disease / prevention & control*
  • Evidence-Based Medicine
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • C-Reactive Protein